GT200300095A - Derivados de isoquinolina - Google Patents

Derivados de isoquinolina

Info

Publication number
GT200300095A
GT200300095A GT200300095A GT200300095A GT200300095A GT 200300095 A GT200300095 A GT 200300095A GT 200300095 A GT200300095 A GT 200300095A GT 200300095 A GT200300095 A GT 200300095A GT 200300095 A GT200300095 A GT 200300095A
Authority
GT
Guatemala
Prior art keywords
isoquinoline derivatives
alzheimer
disorders
record
compounds
Prior art date
Application number
GT200300095A
Other languages
English (en)
Inventor
Andrea Cesura
Rosa Maria Rodriguez Sarmiento
Michelangelo Scalone
Andrew William Thomas
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of GT200300095A publication Critical patent/GT200300095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE ISOQUINOLINA DE FORMULA GENERAL I EN DONDE Z,Y,R1,M, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON INHIBIDORES SELECTIVOS DE MONOAMINA OXIDASA B POR LO QUE SON DE UTILIDAD EN TRASTORNOS TALES COMO ALZHEIMER Y DEMENCIA SENIL.
GT200300095A 2002-04-26 2003-04-24 Derivados de isoquinolina GT200300095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02009253 2002-04-26

Publications (1)

Publication Number Publication Date
GT200300095A true GT200300095A (es) 2004-01-15

Family

ID=29265896

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300095A GT200300095A (es) 2002-04-26 2003-04-24 Derivados de isoquinolina

Country Status (31)

Country Link
US (1) US6818774B2 (es)
EP (1) EP1501804B1 (es)
JP (1) JP4322685B2 (es)
KR (1) KR100681585B1 (es)
CN (1) CN1310890C (es)
AR (1) AR039651A1 (es)
AT (1) ATE440821T1 (es)
AU (1) AU2003227614B2 (es)
BR (1) BR0309562A (es)
CA (1) CA2483461C (es)
DE (1) DE60328978D1 (es)
DK (1) DK1501804T3 (es)
ES (1) ES2329354T3 (es)
GT (1) GT200300095A (es)
HK (1) HK1080836A1 (es)
HR (1) HRP20040952A2 (es)
IL (1) IL164677A0 (es)
MX (1) MXPA04010537A (es)
MY (1) MY133527A (es)
NO (1) NO20044571L (es)
NZ (1) NZ535885A (es)
PA (1) PA8572001A1 (es)
PE (1) PE20040594A1 (es)
PL (1) PL373697A1 (es)
PT (1) PT1501804E (es)
RU (1) RU2318812C2 (es)
SI (1) SI1501804T1 (es)
TW (1) TWI278451B (es)
UY (1) UY27786A1 (es)
WO (1) WO2003091219A1 (es)
ZA (1) ZA200408281B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644367B1 (en) * 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CA2524054C (en) * 2003-05-19 2012-04-24 Irm Llc Immunosuppressant compounds and compositions
ES2754221T3 (es) * 2003-08-29 2020-04-16 Ono Pharmaceutical Co Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo
CN101407471A (zh) 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
DE602004017206D1 (de) * 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
NZ550216A (en) 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
ATE541830T1 (de) 2004-12-13 2012-02-15 Ono Pharmaceutical Co Aminocarbonsäurederivat und dessen medizinische verwendung
JP4934055B2 (ja) * 2005-01-28 2012-05-16 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト イソクロマンおよびその誘導体の製造方法
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
EP1963280B1 (en) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
EA015256B1 (ru) * 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
DE602007012072D1 (de) 2006-04-26 2011-03-03 Actelion Pharmaceuticals Ltd Orantagonisten
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CN105315204B (zh) * 2014-07-04 2018-02-09 中南大学 7‑氨基‑1,4‑二氢异喹啉‑3(2h)‑酮衍生物及其合成方法和用途
CN105585527B (zh) * 2015-12-17 2018-06-26 浙江工业大学 2-(3,4-二氢异喹啉-1(2h)-亚基)乙腈类化合物及其应用
CN105461626B (zh) * 2015-12-17 2018-05-08 浙江工业大学 芳环或稠杂环联3,4-二氢异喹啉类共轭结构化合物及其应用
CN110461829B (zh) * 2017-03-27 2023-02-28 百时美施贵宝公司 作为免疫调节剂的取代的异喹啉衍生物
CN114591238B (zh) * 2022-03-25 2022-11-15 邦恩泰(山东)生物医药科技集团股份有限公司 一种异喹啉类药物中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448269B1 (en) * 1993-07-22 2002-09-10 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
US6137002A (en) * 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
EP0906090A1 (en) 1996-03-15 1999-04-07 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome

Also Published As

Publication number Publication date
AU2003227614B2 (en) 2008-06-26
WO2003091219A1 (en) 2003-11-06
TWI278451B (en) 2007-04-11
SI1501804T1 (sl) 2009-12-31
CA2483461A1 (en) 2003-11-06
PA8572001A1 (es) 2003-12-10
AU2003227614A1 (en) 2003-11-10
RU2318812C2 (ru) 2008-03-10
HRP20040952A2 (en) 2005-06-30
EP1501804A1 (en) 2005-02-02
CN1649844A (zh) 2005-08-03
US6818774B2 (en) 2004-11-16
KR100681585B1 (ko) 2007-02-09
PL373697A1 (en) 2005-09-05
CA2483461C (en) 2010-12-21
ATE440821T1 (de) 2009-09-15
KR20040104628A (ko) 2004-12-10
HK1080836A1 (en) 2006-05-04
RU2004134575A (ru) 2005-07-20
NZ535885A (en) 2007-05-31
PT1501804E (pt) 2009-10-29
JP4322685B2 (ja) 2009-09-02
ZA200408281B (en) 2005-10-14
MY133527A (en) 2007-11-30
TW200307670A (en) 2003-12-16
PE20040594A1 (es) 2004-08-30
CN1310890C (zh) 2007-04-18
JP2005533761A (ja) 2005-11-10
BR0309562A (pt) 2005-02-15
ES2329354T3 (es) 2009-11-25
UY27786A1 (es) 2003-10-31
DK1501804T3 (da) 2009-10-12
NO20044571L (no) 2004-10-22
US20030225122A1 (en) 2003-12-04
AR039651A1 (es) 2005-03-02
MXPA04010537A (es) 2005-01-25
DE60328978D1 (de) 2009-10-08
IL164677A0 (en) 2005-12-18
EP1501804B1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
GT200300095A (es) Derivados de isoquinolina
GT200300284A (es) Derivados de 3h-quinazolin-4-ona
BRPI0414598A (pt) indóis substituìdos
GT200500208A (es) Indazoles ùtiles para tratar enfermedades cardiovasculares
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
GT200300204A (es) Derivados de 4-pirrolidino-fenil-bencil eter
GT200300093A (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
GT200300098A (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
NO20092762L (no) 2-aza-bicyklo[3.1.0]heksanderivater
TW200613274A (en) Organic compounds
NO20062644L (no) DPP-IV inhibitorer
BRPI0511771A (pt) formulações nutricionais
GT200600217A (es) Proceso para la sintesis de compuestos organicos
EA200801607A1 (ru) Производные бензимидазолонкарбоновой кислоты
GT200500215A (es) Amidas sustituidas de àcido tienopirrolcarboxìlico, amidas del àcido pirrolotiazolcarboxìlico y anàlogos relacionados como inhibidores de la epsilon caseìna quinasa i
BRPI0413973A (pt) compostos
GT200300033A (es) Derivados de nicotinamida utiles como inhibidores de pde4
NO20073678L (no) Nye fremgangsmater for fremstilling av benzofuran
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
DE602007013077D1 (de) Organische verbindungen
GT200300119A (es) Derivados de n-acilamino bencil eter
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
GT200300108A (es) Derivados de benzoxazina y usos de los mismos
GT200500317A (es) Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos